Yasuaki Harabuchi

Asahikawa Medical College Hospital — Japan

Medicine · Health Sciences

49h-index7.9kcitations553works0.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(70), Viral-associated cancers and disorders(66), Salivary Gland Tumors Diagnosis and Treatment(52), Immune Cell Function and Interaction(51), Immunotherapy and Immune Responses(48)

Publications553 total

Tonsil-induced autoimmune/inflammatory syndrome: Current insights into the pathogenic role of tonsils in immunoglobulin A nephropathy, palmoplantar pustulosis and psoriasis
Auris Nasus Larynx·2025· 1 cited
Retraction: Chronic Epipharyngitis Treated with Epipharyngeal Abrasion Therapy: Symptoms, Diagnosis, Pathogenesis, and Treatment Outcomes
JMA Journal·2025Open Access
Chronic Epipharyngitis Treated with Epipharyngeal Abrasion Therapy: Symptoms, Diagnosis, Pathogenesis, and Treatment Outcomes
JMA Journal·2025Open Access
Report of the Tenth Hands-on Seminar on Basic Research for Clinicians at the 62nd Annual Meeting of the Japanese Rhinologic Society
Nihon Bika Gakkai Kaishi (Japanese Journal of Rhinology)·2025Open Access
Report of the Ninth Hands-on Seminar on Basic Research for Clinicians at the 61st Annual Meeting of the Japanese Rhinologic Society
Nihon Bika Gakkai Kaishi (Japanese Journal of Rhinology)·2025Open Access
Data from Sustained Persistence of IL2 Signaling Enhances the Antitumor Effect of Peptide Vaccines through T-cell Expansion and Preventing PD-1 Inhibition
2023Open Access
Supplementary Figure Legends from Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses
2023Open Access
Data from Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses
2023Open Access
Supplementary Figure 1 from Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses
2023Open Access
Supplementary Figure 4 from Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses
2023Open Access
Supplementary Figure 1 from Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses
2023Open Access
Supplementary Figure 2 from Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses
2023Open Access
Supplementary Figure 2 from Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses
2023Open Access
Data from Sustained Persistence of IL2 Signaling Enhances the Antitumor Effect of Peptide Vaccines through T-cell Expansion and Preventing PD-1 Inhibition
2023Open Access
Supplementary Figure 4 from Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses
2023Open Access
Supplementary Figures from Sustained Persistence of IL2 Signaling Enhances the Antitumor Effect of Peptide Vaccines through T-cell Expansion and Preventing PD-1 Inhibition
2023Open Access
Supplementary Figure 3 from Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses
2023Open Access
Data from Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses
2023· 1 citedOpen Access
Supplementary Figure 3 from Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses
2023Open Access
Supplementary Figure Legends from Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses
2023Open Access
page 1 of 28Next →

Frequent Co-authors

Miki Takahara(17), Kan Kishibe(15), Toshihiro Nagato(13), Nobuyuki Bandoh(9), Takumi Kumai(9), Esteban Celis(8), Hiroya Kobayashi(8), Takeshi Ogino(7), Hideyuki Ishii(6), Satoshi Nonaka(5), Kensuke Oikawa(5), Naoko Aoki(5), Tatsuya Hayashi(5), Akikatsu Kataura(4), Takayuki Ohkuri(4), Naoyuki Miyokawa(4), Soldano Ferrone(4), Seigo Ueda(4), Shizuo Kojya(4), Katsuyuki Aozasa(4)